Home > Boards > US OTC > Medical - Drugs >

Aralez Pharmaceuticals Inc. (ARLZQ)

Add ARLZQ Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/2/2018 6:08:38 AM - Followers: 42 - Board type: Free - Posts Today: 0


Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. It also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women?s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, its out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company is headquartered in Milton, Canada.

Corporate Governance

Aralez Pharmaceuticals Inc.’s ISS Governance QualityScore as of March 2, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Aralez Pharmaceuticals Inc.

151 Steeles Avenue East
Milton, ON L9T 1Y1

Full Time Employees:

Key Executives

Name Title Pay Exercised Age
Mr. Adrian Adams Chief Exec. Officer and Director 1.02M N/A 66
Mr. Andrew I. Koven Pres and Chief Bus. Officer 683.18k N/A 59
Mr. Scott J. Charles Chief Financial Officer 653.07k N/A 42
Mr. Mark A. Glickman Chief Commercial Officer 504.94k N/A 51
Mr. John E. Barnhardt CPA Principal Accounting Officer and VP of Fin. & Admin. N/A N/A 67
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Aralez Reports First Quarter 2017 Financial Results



Aralez Pharmaceuticals Inc. 

09 May, 2017, 07:00 ET



-First Quarter 2017 Net Revenues of $26.0 Million-

-Cost Savings Plan Expected to Reduce 2017 Expenses by $23.0 Million; Improved 2017 Adjusted EBITDA Guidance-


-Currently Implementing a Bold Program Aimed at Allowing All Patients to Access Yosprala for Only $10.00 Per Month-

MISSISSAUGA, Ontario, May 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced financial results for the first quarter ended March 31, 2017. The Company also highlighted certain recent corporate and commercial achievements. All figures are in U.S. dollars.

"We are pleased to report a solid first quarter of 2017, together with important updates to our business addressing a number of the challenges we face," said Adrian Adams, Chief Executive Officer of Aralez. "We are making a bold and significant change to our pricing strategy for Yosprala® aimed at allowing all patients to access the product for only $10.00 per month. In addition, we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility. Our updated financial guidance for 2017 reflects our commitment to reaching break-even on an Adjusted EBITDA basis this year. We also continue to opportunistically look at business development opportunities with a strong focus on value creating and transformative M&A with the goal of enhancing shareholder value."

Company Highlights:

  • The Company is currently implementing a bold, patient friendly program aimed at allowing all patients to access Yosprala for only $10.00 per month, regardless of coverage or copay level set by the insurer. This program will be available for all patients through retail pharmacies or through select national mail order partners.
    The Company has begun implementing cost savings initiatives that are expected to reduce our 2017 operating expenses by approximately $23.0 million, of which approximately $9.0 million was included in our original 2017 Adjusted EBITDA guidance. In addition, the Company has also identified other initiatives to drive an increase in profitability, such as an increased focus on the Canadian core growth brands and the Board of Directors recent decision to reduce the cash portion of their fees for 2017 by half.
    On May 8, 2017, Aralez subsidiary Pozen Inc. (Pozen) entered into a license agreement with a multi-national pharmaceutical company pursuant to which Pozen granted a non-exclusive license to such company under a Japanese patent owned by Pozen. The non-exclusive license is limited to Japan. In consideration for this non-exclusive license, Pozen will receive an upfront payment of $4.0 million, plus contingent milestone payments and royalties under certain circumstances.
    On April 24, 2017, the Company commenced its phased launch of Zontivity® utilizing 15 sales representatives deployed to high volume physicians who treat post-myocardial infarction (MI) and Peripheral Artery Disease (PAD) patients. The Phase 2, full-scale launch is expected to begin in early June 2017 with 75 sales representatives targeting approximately 12,000 physicians made up of cardiologists, primary care and vascular surgeons.
    On April 6, 2017, Aralez Pharmaceuticals US Inc. (APUS) and the United States Government (the Government) entered into a Modification of Contract for Toprol-XL® pursuant to which the Government exercised its first renewal option under the VA National Contract between APUS and the Government (the VA Contract), extending the term of the VA Contract by one year to April 28, 2018 with reduced pricing for the duration thereof. 

"Deerfield Partners remains fully supportive of Aralez and its management team as the company navigates its way through recent challenges," said James Flynn, Managing Partner at Deerfield. "We are encouraged by the new pricing strategy for Yosprala and the prospects for Zontivity."

Cost Savings Initiatives 
The Company previously announced in April 2017 that it had begun implementing cost savings initiatives as part of the Company's ongoing objective to maximize value from its assets and preserve financial flexibility. The total expected operating expense reduction in 2017 of approximately $23.0 million includes the previously announced 32% reduction in its U.S. sales force, which is expected to yield 2017 savings of approximately $5.5 million ($7.5 million on an annual basis), a decrease of approximately $9.0 million in 2017 commercial spend, which primarily relates to non-direct marketing spend on Yosprala, and decreased 2017 departmental expenses across the business of approximately $8.5 million. While Aralez has made significant reductions to its expenses, the Company plans to invest an additional $7.0 million to support a successful phased launch of Zontivity that commenced on April 24, 2017, which the Company views as an increasingly attractive opportunity. The Company also continues to assess various business development opportunities with the goal of providing improved cash flow and an enhanced platform for creating value.

First Quarter 2017 Financial Results 
Aralez's financial results for the three months ended March 31, 2016 include the operations of Tribute Pharmaceuticals Canada Inc. (Tribute) from February 5, 2016, the closing date of the Pozen and Tribute merger transaction (the Merger), through March 31, 2016, but do not include the results of Zontivity or Toprol-XL and its currently marketed authorized generic (the Toprol-XL franchise) as these acquisitions were completed on September 6, 2016 and October 31, 2016, respectively. Aralez's financial results for the three months ended March 31, 2017 include the results of Tribute, Zontivity and the Toprol-XL franchise.

Total revenues for the three months ended March 31, 2017 were $26.0 million compared to $8.1 million for the three months ended March 31, 2016. Net product revenues of $6.7 million for the three months ended March 31, 2017 primarily related to the product portfolio acquired with the acquisition of Tribute as well as net product revenues from Yosprala and Fibricor®. Other revenues of $19.3 million for the three months ended March 31, 2017 were comprised of net revenues of $15.6 million from the acquisitions of the Toprol-XL franchise and Zontivity, which are recorded net of related cost of product revenues and fees paid during the respective transition service periods, and Vimovo® royalties of $3.7 million. Pursuant to the Company's agreement with Horizon in the U.S., subject to certain conditions described in our public filings, Aralez is guaranteed a quarterly minimum royalty amount (calculated based on a minimum annual royalty of $7.5 million), which was reflected in the Company's first quarter results. Net product revenues of $3.6 million for the three months ended March 31, 2016 related to the Tribute product portfolio acquired in the Merger, which was completed on February 5, 2016. Other revenues of $4.5 million for the three months ended March 31, 2016 were comprised solely of Vimovo royalties.

Cost of product revenues were $2.8 million for the three months ended March 31, 2017 compared to $2.5 million for the three months ended March 31, 2016. The increase related primarily to costs of product revenues for the full quarter in 2017 from the Company's product portfolio that was acquired as part of the Merger in February 2016.

SG&A expenses were $30.8 million for the three months ended March 31, 2017 compared to $37.5 million for the three months ended March 31, 2016. The decrease in SG&A expenses was primarily driven by costs related to the Merger in the prior year of approximately $19.4 million, partially offset by increased costs related to the build out of our U.S. sales force in 2016 and increased promotional expenses in the U.S. during the first quarter of 2017.

R&D expenses for the three months ended March 31, 2017 were $0.1 million compared to $4.4 million for the three months ended March 31, 2016. The decrease related primarily to higher costs incurred in the first quarter of 2016 for Yosprala in advance of its U.S. approval in September 2016.

Amortization of intangible assets of $8.5 million for the three months ended March 31, 2017 related to the acquisitions of Tribute, Zontivity and the Toprol-XL franchise. Amortization of intangible assets for the three months ended March 31, 2016 of $1.3 million related solely to the acquisition of Tribute.

The change in fair value of contingent consideration of $4.4 million for the three months ended March 31, 2017 related to accretion for the Toprol-XL franchise and Zontivity acquisitions. There was no expense related to fair value changes in contingent consideration for the three months ended March 31, 2016.

Interest expense of $6.7 million for the three months ended March 31, 2017 was primarily attributable to the borrowing of $200 million under the Company's credit facility in the fourth quarter of 2016 in connection with the acquisitions of Zontivity and the Toprol-XL franchise and $75 million convertible notes. Interest expense of $0.3 million for the three months ended March 31, 2016 related to the $75 million convertible notes.

Other income, net for the three months ended March 31, 2017, was $0.4 million compared to $4.8 million for the three months ended March 31, 2016, a decrease of $4.4 million. The decrease principally related to a $4.6 million decrease in the fair value of the warrants liability acquired from Tribute during the prior year, offset by a $0.3 million gain from the sale of a building in London, Ontario during the three months ended March 31, 2017.

The net loss for the three months ended March 31, 2017 was $27.5 million, or $0.42 loss per share on a fully diluted basis, compared to a net loss for the three months ended March 31, 2016 of $33.8 million, or $0.73 loss per share on a fully diluted basis.

Adjusted EBITDA was ($3.6) million for the three months ended March 31, 2017 compared to Adjusted EBITDA of ($11.1) million for the three months ended March 31, 2016.

Balance Sheet 
As of March 31, 2017, approximately 65.8 million of the Company's common shares were issued and outstanding and the Company had cash and cash equivalents of approximately $73.7 million.

Updated 2017 Guidance 
Aralez's estimates are based on projected results of the Company for the year ending December 31, 2017 and reflect management's current beliefs and expectations about, among other things, prescription trends, competition, pricing levels, inventory levels, and anticipated future events. The Company's guidance on Adjusted EBITDA includes, among other things, costs to support the commercialization efforts with respect to Yosprala, Zontivity and the Canadian product portfolio as well as costs to support the global corporate structure. It excludes share-based compensation expense and certain discrete costs, including merger and product acquisition-related expenses. See "Use of Non-GAAP Financial Measures" below.   

For the year ending December 31, 2017, assuming, among other factors more particularly set out in "Cautionary Note Regarding Forward-Looking Statements" below, the Company currently expects:

  • 2017 Net Revenues to be in a range of $80 million to $100 million; and
    Updated 2017 Adjusted EBITDA to be in a range of $(5) million to $5 million.

See the table below for a comparison of the Company's original 2017 guidance compared to the updated 2017 guidance:



2017 Original Guidance

2017 Updated Guidance

Net Revenues

$80 million to $100 million

$80 million to $100 million

Adjusted EBITDA

$(25) million to $(10) million

$(5) million to $5 million

First Quarter Results Webcast 
Aralez will host a webcast this morning, May 9, 2017 at 9:00 a.m. ET to present results for the first quarter 2017. The webcast can be accessed live and will be available for replay at www.aralez.com.

Conference Call Details 
Date: Tuesday, May 9, 2017 
Time: 9:00 a.m. ET 
Dial-in (U.S.): 877-407-8037  
Dial-in (International): 201-689-8037

About Aralez Pharmaceuticals Inc. 
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ARLZQ News: Current Report Filing (8-k) 11/02/2018 05:22:31 PM
ARLZQ News: Current Report Filing (8-k) 10/05/2018 04:44:56 PM
ARLZQ News: Current Report Filing (8-k) 10/01/2018 04:47:36 PM
ARLZQ News: Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... 09/27/2018 09:19:11 AM
ARLZQ News: Current Report Filing (8-k) 09/19/2018 05:28:06 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#364   Depends on the bidders in the staking horse local 11/02/18 06:08:38 AM
#363   What you think? .005-.007 this may drop to. Big Poppa Pump 10/31/18 08:01:21 PM
#362   Check out the monthly operating report filed on local 10/31/18 06:58:49 PM
#361   A stalking horse offer, agreement, or bid is Willie2002 10/23/18 08:53:39 PM
#360   Please explain what a stalking horse bid is? heyyou2 10/11/18 08:59:00 PM
#359   Liabilities in the hundred million dollar range? Drugdoctor 09/26/18 08:08:43 AM
#358   Something's happening. Usually, with these Q stocks, Lone Wolf 09/26/18 08:06:12 AM
#357   Yep. When a Q stock that has Lone Wolf 09/25/18 07:54:01 PM
#356   Lets go LW ! CarlCarlMcB 09/25/18 05:09:55 PM
#355   23.5mil in assets here. Stalking Horse's bid Lone Wolf 09/25/18 03:46:02 PM
#354   I wonder if anyone realizes that there is Lone Wolf 09/25/18 03:28:09 PM
#353   ARLZQ took a starter here @.023 Technically speaking 08/31/18 12:32:18 PM
#352   It's doing great today, I see... Drugdoctor 08/24/18 10:19:21 AM
#351   As said, it's all for trading. It'll take hondaboost 08/24/18 10:06:08 AM
#350   Great - Good luck with the liquidation stock... Drugdoctor 08/24/18 10:03:01 AM
#349   ARLZ, 52 week high: $2.98. Those who bought hondaboost 08/24/18 10:00:44 AM
#348   It's all for trading: those who bought at hondaboost 08/24/18 09:55:09 AM
#347   LIQUIDATION - means it's done bud... I already Drugdoctor 08/23/18 11:44:48 AM
#346   You averaged down at $0.30's? Now, it's only hondaboost 08/23/18 11:41:48 AM
#345   Wow! ARLZ, from $2.98 to $0.02 ! What hondaboost 08/23/18 11:36:25 AM
#344   ARLZ changed to ARLZQ. Delisted from the Nasdaq Renee 08/21/18 09:28:14 AM
#343   Heads up for those who don't know. I Ihubpebs 08/17/18 10:44:59 AM
#342   Yea, I was WRONG about the bounce, but Drugdoctor 08/14/18 08:04:51 AM
#341   * * $ARLZ Video Chart 08-13-18 * * ClayTrader 08/13/18 05:56:25 PM
#340   Nice bounc surge1k 08/13/18 10:07:51 AM
#339   * * $ARLZ Video Chart 08-10-18 * * ClayTrader 08/10/18 05:53:06 PM
#338   Put it into QTMM and at least recover ih8aloss 08/10/18 01:30:59 PM
#337   Yes, and with LIQUIDATION... no need to hope Drugdoctor 08/10/18 11:53:20 AM
#336   you called it Doc..... ecmoney 08/10/18 11:51:14 AM
#335   I warned of this BANKRUPTCY on July 6th- Drugdoctor 08/10/18 10:57:09 AM
#334   CLAY only knows how to draw horizontal lines. willlbone 08/10/18 10:48:31 AM
#333   another broken company where CLAY has uploaded videos jpowellvlc 08/10/18 10:04:31 AM
#332   lol going to 000000 its BK Crumbster 08/10/18 09:48:14 AM
#331   everyone is selling going to .01 ecmoney 08/10/18 09:34:12 AM
#330   wow ecmoney 08/10/18 08:53:43 AM
#329   $250M agreement? TheKobra 08/10/18 06:54:40 AM
#328   Sweetness to my ears Switch300 08/10/18 06:45:05 AM
#327   * * $ARLZ Video Chart 08-09-18 * * ClayTrader 08/09/18 05:28:15 PM
#326   What a dud Crumbster 07/24/18 03:47:40 PM
#325   * * $ARLZ Video Chart 07-23-18 * * ClayTrader 07/23/18 04:07:27 PM
#324   Bid / Ask in Premarket is looking good. aristotelisonassis 07/23/18 07:33:42 AM
#323   Dead cat bounce or some fundamental reason for Drugdoctor 07/22/18 08:06:50 PM
#322   * * $ARLZ Video Chart 07-20-18 * * ClayTrader 07/20/18 04:15:26 PM
#321   very cheap here. Strong buy! aristotelisonassis 07/20/18 11:35:41 AM
#320   With you on this one this is dying island man 07/20/18 02:04:09 AM
#319   I'd wait for an earnings report... they may Drugdoctor 07/18/18 07:52:37 PM
#318   i have been watching arlz since may ecmoney 07/18/18 11:28:39 AM
#317   I hear you ADXS was the thorn in island man 07/13/18 12:09:44 PM
#316   Yea, I sold after the annual meeting when Drugdoctor 07/12/18 09:54:40 PM
#315   Yeah and it looks like ADXS is on island man 07/12/18 07:54:07 PM